Houqiang Yu

Dr. Houqiang Yu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2020 in Sensors
Verified
Journal Article
Open access
PDF file
HYHouqiang Yu
Houqiang Yu
Xuming  ZhangXuming Zhang
Xuming Zhang
Prostate cancer remains a major health concern among elderly men. Deep learning is a state-of-the-art technique for MR image-based prostate cancer diagnosis, but one of major bottlenecks is the severe lack of annotated MR images. The traditional and Generative Adversarial Network (GAN)-based data augmentation methods cannot ensure the quality and the diversity of generated training samples. In this paper, we have proposed a novel GAN model for synthesis of MR images by utilizing its powerful ability in modeling the complex data distributions. The proposed model is designed based on the architecture of deep convolutional GAN. To learn the more equivariant representation of images that is robust to the changes in the pose and spatial relationship of objects in the images, the capsule network is applied to replace CNN used in the discriminator of regular GAN. Meanwhile, the least squares loss has been adopted for both the generator and discriminator in the proposed GAN to address the vanishing gradient problem of sigmoid cross entropy loss function in regular GAN. Extensive experiments are conducted on the simulated and real MR images. The results demonstrate that the proposed capsule network-based GAN model can generate more realistic and higher quality MR images than the compared GANs. The quantitative comparisons show that among all evaluated models, the proposed GAN generally achieves the smallest Kullback–Leibler divergence values for image generation task and provides the best classification performance when it is introduced into the deep learning method for image classification task.

1 September 2026 in Gels
Verified
Journal Article
Open access
PDF file
LLLi Ling
Li Ling
王克王 克辛
王 克辛
ZSZhe Song
Zhe Song
HTHongan Tian
Hongan Tian
CWCai Wang
Cai Wang
HYHouqiang Yu
Houqiang Yu
TPZ is a hypoxia-activated anticancer agent that exerts selective cytotoxicity within hypoxic tumor microenvironments. Although intratumoral injection of TPZ can achieve localized antitumor activity, the drug is prone to rapid diffusion and clearance from the injection site, limiting its long-term retention and thereby reducing therapeutic durability and overall efficacy. To achieve sustained release and prolonged retention of TPZ in subcutaneous tumors, a thermosensitive nanogel loaded with TPZ (TPZ@PNA-TNG) was developed. By thoroughly mixing 3 mg/mL TPZ with 6 wt% PNA-TNG, the resulting formulation enabled continuous slow release of TPZ following intratumoral injection, resulting in favorable therapeutic outcomes. The sol–gel phase transition behavior of TPZ@PNA-TNG was investigated using the inverted vial method and rheological measurements. In vivo antitumor studies demonstrated that a single administration of TPZ@PNA-TNG effectively suppressed tumor progression, with tumor volume decreasing to 0.72 ± 0.04 times its initial size over a 14-day period. Mechanistically, TPZ@PNA-TNG markedly enhanced antitumor immune responses, inhibited tumor cell proliferation, promoted apoptosis and anti-angiogenesis, and ultimately induced extensive ischemic necrosis within subcutaneous tumors. In addition, owing to the prolonged intratumoral retention capability of PNA-TNG, TPZ@PNA-TNG enabled sustained local delivery of TPZ, thereby significantly reducing systemic toxicity and adverse effects associated with TPZ while maintaining favorable biocompatibility. These findings highlight the therapeutic potential of TPZ@PNA-TNG for cancer therapy applications.

24 January 2026 in ACS Omega
Verified
Journal Article
Open access
LLLi Ling
Li Ling
NCNing Chen
Ning Chen
GCGuotao Cheng
Guotao Cheng
ALAnna Liu
Anna Liu
LZLing Zhang
Ling Zhang
CZChuansheng Zheng
Chuansheng Zheng
The development of liquid embolic agents has significantly advanced the field of transcatheter arterial embolization (TAE). Conventional solid embolic agents, such as gelatin sponges or poly-(vinyl alcohol) (PVA), are limited by their lack of intrinsic radiopacity and reliance on lipiodol, necessitating a cumbersome two-step embolization process. Consequently, a critical need exists for embolic materials that combine intrinsic imaging functionality with enhanced biocompatibility to advance clinical outcomes. We have developed a novel liquid embolic material based on poly-(N-isopropylacrylamide)-co-acrylic acid nanogels (PNAs). Mixing PNAs with lipiodol using a medical three-way stopcock yields a thermosensitive lipiodol-based gel emulsion (TLGE). This material exhibits excellent temperature sensitivity and biocompatibility. Notably, the TLGE demonstrates injectable fluidity and sufficient X-ray contrast in an ex vivo decellularized liver model. This embolization technique requires only a single injection and allows for rapid mixing, offering significant practical advantages in the clinic. Digital subtraction angiography (DSA) facilitates intraoperative imaging and real-time monitoring of the embolization process, aiding in the prevention of nontarget embolization and ensuring precise treatment. In a preclinical study, following the embolization of the right renal artery in New Zealand rabbits, a 42-day observation period revealed no instances of vessel recanalization or damage to nontarget organs. Consequently, this innovative temperature-sensitive material demonstrates significant potential for clinical application in TAE procedures.

22 January 2026 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
LLLing Li
Ling Li
ALAnna Liu
Anna Liu
CWCai Wang
Cai Wang
LZLing Zhang
Ling Zhang
HYHouqiang Yu
Houqiang Yu
HZHongfu Zhou
Hongfu Zhou